Stimulant Laxative Drug Class List

Drugs in Drug Class: Stimulant Laxative

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes			Y
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes			Y
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes			Y

Stimulant Laxative Market Dynamics and Patent Landscape

Last updated: April 24, 2026

What defines the “stimulant laxative” market?

Stimulant laxatives are a therapeutic class used to treat constipation by increasing intestinal motility and/or altering intestinal secretion. Commercial products typically fall into three buckets by mechanism and formulation:

• Contact (local) stimulants: commonly bisacodyl and sodium picosulfate, often formulated as tablets, dragees, drops, or suppositories.
• Anthraquinone-derived stimulant laxatives: historically include senna (and extracts).
• Combination constipation products: stimulant + stool softener, stimulant + osmotic agent, or stimulant + bulking agent, marketed for “daily” or “relief” regimens.

The patent landscape is driven by the fact that many stimulant laxatives are mature, with older foundational compositions and broad method-of-use coverage. Commercial differentiation increasingly comes from:

• Formulation (e.g., delayed-release, prodrug-like delivery for picosulfate/bisacodyl derivatives, controlled-release matrices).
• Dosage regimens (signal timing for “morning” vs “night” relief).
• Route and device integration (e.g., suppositories; sometimes inhalation is not typical for laxatives, so focus remains on oral and rectal).
• Patient segmentation (pediatric dosing forms, geriatric-adapted products, and OTC-to-prescription switches where applicable).

Where does the value pool sit: OTC legacy brands vs Rx specialty?

Stimulant laxatives are predominantly consumer-facing and OTC-heavy in many markets, which compresses sustainable pricing and increases the weight of:

• Channel access (pharmacy and drugstore shelf placement),
• Brand recognition,
• Generics competition, and
• Payer tolerance for low-cost treatments when used episodically.

Where value can persist longer is often linked to:

• Brand-protected formulations (not the active ingredient itself),
• Extension filings on device-like delivery or improved pharmacokinetics,
• Line extensions tied to specific dosing, taste-masking, or pediatric formulations,
• Combination products where the exact pairing and ratio are protected.

How do market dynamics shape competition?

Competitive intensity is high because:

• Core actives are old,
• Many jurisdictions grant fast generic entry once composition and approved indications are cleared, and
• Regulatory pathways favor equivalence for conventional solid oral dosage forms.

Practically, the market behaves like:

• Periodic demand (constipation is chronic for many, episodic for others; stimulant use is often intermittent or rescue therapy).
• Switching is common due to price sensitivity and therapeutic interchangeability within the class.
• Differentiation shifts from molecule to product: dose timing, onset profile positioning, pediatric usability, and tolerability.

In this class, patent life typically matters most at the margins: the formulation envelope, the dosing schedule claims, and any proprietary combinations.

---

What does the patent landscape look like for stimulant laxatives?

Key reality: most “composition” patents are long expired

For stimulant laxatives, foundational chemistry and early composition coverage for:

• Bisacodyl
• Sodium picosulfate
• Senna extracts are generally not the main drivers of today’s litigation or ongoing exclusivity. Instead, modern patent activity tends to concentrate on:
• Improved pharmaceutical compositions (including excipient systems, coatings, and delayed-release approaches),
• Specific dosing regimens and patient subgroups (where supported),
• Combination formulations (new ratios and manufacturing processes),
• Methods of using a known stimulant within a new therapeutic context (less frequent than formulation IP).

Claim strategy trends

Patent filings across the class commonly pursue one or more of these:

• Independent composition claims for a defined dosage form, coating, or excipient system.
• Dependent claims around particle size, coating thickness, dissolution profile targets, and manufacturing parameters.
• Method-of-treatment claims that tie to timing or onset targets (for example, “evening dosing produces next-morning bowel movement” claims), where permitted.
• Combination claims that lock in a specific pairing with an osmotic agent or stool softener at a defined ratio.

Litigation posture

Where disputes occur in stimulant laxatives, they tend to be less about inventing new chemistry and more about:

• whether a generic’s formulation meets claim limitations tied to coatings/dissolution profile or combination ratios,
• whether method claims are infringed via dosing instructions in product labeling,
• and whether the patent is still enforceable given regulatory approvals and any exclusivity timing.

---

Which active ingredients anchor the patent and market map?

Below is a high-level anchor map of the class. It is not an exhaustive patent list. It is a market-oriented scaffold that shows where commercial product differences and most likely IP concentration occur.

Active stimulant laxative	Typical commercial formats	Differentiation lever most often protected	Patent relevance today
Bisacodyl	tablets, dragees, suppositories	coatings/dissolution timing; dosage-form specs; prodrug-like behavior via formulation	Typically formulation and regimen claims, not new chemical entity
Sodium picosulfate	drops, tablets	delivery and conversion timing; onset targeting via formulation	Formulation and combination strategies dominate
Senna / senna glycosides	tablets, teas, extracts	extract standardization, dosing standardization; combination products	Plant-derived actives often face weaker composition patentability; formulation is key
Combination products (stimulant + other laxatives)	tablets/sachets with multiple agents	specific ratios, coatings, and manufacturing process	Most active IP zone for “line extensions”

---

How does exclusivity interact with generic entry?

Stimulant laxatives largely follow the generic lifecycle typical for established OTC or widely used Rx products:

1. Brand builds via labeling and packaging.
2. Generics erode price and market share once composition patents clear.
3. Brands extend through formulation and combination filings where patentable.
4. Payers and consumers shift toward the cheapest equivalent unless the branded product retains a protected formulation advantage.

Key investment implication: the “headline molecule” is rarely the primary moat. The moat is usually:

• protected dosage form performance (release/dissolution targets),
• protected combination recipe, or
• protected pediatric or route-specific presentation.

---

What should an R&D team treat as the highest-value patent targets?

For stimulant laxatives, the most realistic near-term patentable spaces are:

1. Delayed-release or targeted-release dosage forms

   • Focus on measurable dissolution and onset timing.
   • Claim systems that map to in-vitro performance metrics are the most defensible for enforcement.

2. Coating or excipient-engineered performance

   • Coating chemistry and thickness alone may be weak without a full performance claim strategy.
   • Better approach is to tie formulation features to a defined product performance window.

3. Combination formulations

   • Stimulant + osmotic or stimulant + stool softener at defined ratios.
   • Claim the combination across a defined dosing regimen and target outcomes.

4. Patient-segmented dosing forms

   • Pediatric-friendly unit dosing, palatability improvements, and stable low-dose presentations can support incremental IP even for known actives.

---

How should investors assess patent durability in this class?

A durable patent position in stimulant laxatives generally requires:

• Clear claim scope tied to product-specific measurable characteristics.
• Non-trivial differences from earlier filings (formulation, not just the active).
• Regulatory coherence: labeling and clinical data aligned to the claimed use or performance objective.
• Limited generic “design-around” options, especially where claim limitations depend on coating and release profile rather than broad method concepts.

If a patent is only composition-level without clear performance constraints, generic design-arounds are more likely. If it is tied to combination ratios or a defined dosage-form performance window, enforceability is higher.

---

Key Takeaways

• Stimulant laxatives are mature actives; the patent moat usually sits in formulation, coatings, release profile, dosing regimen, and combinations, not new chemistry.
• Market dynamics push competition toward price and interchangeability, which makes product-level differentiation the main driver of continued brand value.
• For R&D and investment screening, prioritize patents with measurable, dosage-form-specific claim limitations and combination recipes that are harder for generics to reproduce without crossing claim boundaries.

---

FAQs

1) What part of a stimulant laxative product is most often protected by patents?

The most common protected areas are dosage-form design (coatings, release characteristics), combination ratios, and dosing/regimen-linked performance rather than the underlying old active chemistry.

2) Why do generic products enter quickly in this class?

Because many stimulant laxative actives are established and widely approved, and because equivalence-based regulatory pathways allow rapid substitution once key composition or protected formulation claims expire.

3) What evidence signals stronger enforceability in stimulant laxative patents?

Patents that tie claims to measurable formulation performance (release/dissolution windows) and to specific combination compositions are typically more enforceable than broad method claims.

4) Where do brands typically focus line extensions?

Brands usually focus on delayed-release timing claims, pediatric usability, and combination products that offer a distinct regimen or tolerability profile.

5) What is the most realistic path to a durable moat?

A durable moat is usually achieved by protecting the product performance envelope (formulation engineering) and/or a defined combination recipe, with labeling that aligns to claimed outcomes.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drug approvals and labels (varies by product). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Intellectual Property Organization. (n.d.). Patent information and search tools. https://patentscope.wipo.int/
[3] European Medicines Agency. (n.d.). EPARs and product information (varies by product). https://www.ema.europa.eu/en/medicines